|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:acquired_by
|
gptkb:Shire_plc
|
|
gptkbp:acquisition
|
gptkb:Partnerships
strategic alliance
asset purchase
stock purchase
|
|
gptkbp:acquisition_year
|
gptkb:2016
|
|
gptkbp:ceo
|
gptkb:M._Christine_Carr
|
|
gptkbp:employees
|
approximately 16,000
|
|
gptkbp:focus_area
|
rare diseases
biologics
plasma-derived therapies
|
|
gptkbp:founded
|
gptkb:2015
|
|
gptkbp:headcount
|
16000
|
|
gptkbp:headquarters
|
gptkb:Bannockburn,_Illinois
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Baxalta Incorporated
|
|
gptkbp:industry
|
gptkb:pharmaceuticals
|
|
gptkbp:key_people
|
gptkb:Robert_E._Mc_Mahon
F. Michael Ball
G. Thomas Mc Lain
|
|
gptkbp:market_cap
|
$32 billion (2016)
|
|
gptkbp:parent_company
|
gptkb:Shire_plc
|
|
gptkbp:partnership
|
gptkb:World_Federation_of_Hemophilia
gptkb:American_Red_Cross
gptkb:National_Hemophilia_Foundation
Blood Centers of America
Global Blood Therapeutics
|
|
gptkbp:philanthropy
|
research funding
community health initiatives
education and awareness campaigns
patient support programs
Baxalta Foundation
|
|
gptkbp:products
|
oncology treatments
immunology treatments
hemophilia treatments
|
|
gptkbp:research_focus
|
gptkb:gene_therapy
clinical trials
monoclonal antibodies
plasma collection
biomanufacturing
|
|
gptkbp:revenue
|
$4.5 billion (2015)
|
|
gptkbp:stock_symbol
|
BXLT
|
|
gptkbp:subsidiary
|
Baxalta US Inc.
Baxalta Innovations
Baxalta Manufacturing
Baxalta Therapeutics
|
|
gptkbp:traded_on
|
gptkb:NYSE
|
|
gptkbp:website
|
www.baxalta.com
|
|
gptkbp:bfsParent
|
gptkb:Shire_Pharmaceuticals_Group_plc
|
|
gptkbp:bfsLayer
|
6
|